BioWorld: Alpha Biopharma lands deal for Wugen’s memory NK and CAR T cells for Asia
BioWorld, David Ho, March 2021.
Read MoreBioWorld, David Ho, March 2021.
Read MoreST. LOUIS, MO, March 8, 2021 /PRNewswire/ – Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced…
Read MoreSt. Louis Business Journal, Nathan Rubbelke, March 2021
Read MoreST. LOUIS, MO, March 2, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms, today announced that it has entered into an exclusive license…
Read MoreST. LOUIS, March 1, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of the company’s co-founder, Matt Cooper, Ph.D., as…
Read MoreSt. Louis Business Journal, Nathan Rubbelke, February 2021
Read MoreST. LOUIS, MO, February 22, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, today announced that it has entered into an exclusive license agreement…
Read MoreST. LOUIS, February 22, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of Jan Davidson M.D., Ph.D., as the company’s…
Read MoreBiospace, Kate Goodwin, January 2021
Read More